| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2021: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2020: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Compared with lung tissue and sputum derived from healthy subjects, patients with ACO showed a decrease in percentages of RSS-producing enzyme-positive cells, an increase in NFκB expression, a decrease in GR expression, and a decrease in HDAC2 activity. Furthermore, in BEAS-2B cells with decreased RSS-producing enzyme expression, enhanced NFκB expression, decreased GR expression, and decreased HDAC2 activity were observed. Currently, we are investigating changes in RNS production model, NFκB / GR expression after steroid pretreatment, HDAC2 activity, and anti-inflammatory effect. Furthermore, RSS-producing enzymes are overexpressed, and the effects of NFκB / GR expression, HDAC2 activity, and the degree of anti-inflammatory effect after steroid pretreatment are under investigation. It is suggested that decreased RSS production may be involved in steroid resistance through enhanced NFκB expression, decreased GR expression, and decreased HDAC2 activity.
|
